Humanwell Healthcare (600079) H2 2024 earnings summary

Executive summary

• Revenue reached ¥25.44 billion, up 3.71% year-over-year; net profit attributable to shareholders was ¥1.33 billion, down 37.70% year-over-year, mainly due to increased expenses and asset impairments.

• Core business segments maintained stable growth, with notable performance in neurological drugs and steroid hormones.

• R&D investment totaled ¥1.63 billion, 6.41% of revenue, with 24 clinical approvals and 97 production approvals.

• International expansion advanced, with U.S. generic drug revenue at ¥2 billion and European/ African markets contributing significantly.

• Cash dividend payout for 2024 was ¥767 million, representing 57.69% of net profit.

Financial highlights

• Operating income: ¥25.44 billion (+3.71% YoY); net profit attributable to shareholders: ¥1.33 billion (-37.70% YoY).

• Gross margin: 44.52%, down 1.28 percentage points YoY.

• Basic EPS: ¥0.82 (-37.88% YoY); ROE: 7.67% (-5.65pp YoY).

• Operating cash flow: ¥2.16 billion (+10.01% YoY).

• R&D expenses: ¥1.47 billion (+0.59% YoY).

Outlook and guidance

• 2025 revenue target set above ¥27 billion, with gross margin expected to exceed 45%.

• Focus on strengthening core product lines, digital transformation, and international market expansion.

• Continued high R&D investment, aiming for annual R&D spend above 10% of industrial revenue.